Advertisement

Topics

Heplisav Postmarketing Worries Push PDUFA Date Back; FDA Seeks More Details

14:31 EDT 4 Aug 2017 | SCRIP

Dynavax's final pivotal trial for hepatitis B candidate was missing data from 150 patients, making its causality of myocardial infarctions...

      

Related Stories

 

Original Article: Heplisav Postmarketing Worries Push PDUFA Date Back; FDA Seeks More Details

NEXT ARTICLE

More From BioPortfolio on "Heplisav Postmarketing Worries Push PDUFA Date Back; FDA Seeks More Details"

Quick Search
Advertisement
 

Relevant Topic

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...